

We claim:

1. A method for increasing the survival or growth of motoneurons comprising  
exposing the motoneurons to a low molecular weight heparin.

5 *defined in spec.*

2. A method for preventing of a motoneuron disease in a patient in need  
thereof comprising administering to the patient a pharmaceutically effective  
amount of a low molecular weight heparin.

112, 148

10 3. The method according to claim 2 wherein the motoneuron disease is  
amyotrophic lateral sclerosis, progressive spinal muscular atrophy, infantile  
muscular atrophy or lateral sclerosis.

4. The method according to one of claims 1 to 3, wherein the low molecular  
15 weight heparin has a mean molecular weight of between 1000 and 10000 daltons.

5. The method according to claim 4, wherein the low molecular weight  
heparin has a mean molecular weight of between 1500 and 6000 daltons.

20 6. The method according to claim 4, wherein the low molecular weight  
heparin has a mean molecular weight of between 4000 and 5000 daltons.

7. The method according to one of claims 1 to 3, wherein the low molecular  
weight heparin consists of oligosaccharides having a 2-O-sulfo-  
25 4-enopyranosuronic acid at one of their ends.

8. The method according to one of claims 1 to 3, wherein the low molecular  
weight heparin is obtained by depolymerization of a heparin ester using a base.

*not further  
nitroglycerine*

30 9. The method according to one of claims 1 to 3, wherein the low molecular  
weight heparin is enoxaparin.

10. The method according to one of claims 1 to 3, wherein the low molecular weight heparin is nadroparin.

5

11. The method according to one of claims 1 to 3, wherein the low molecular weight heparin is parnaparin.

12. The method according to one of claims 1 to 3, wherein the low molecular weight heparin is reviparin.

10 13. The method according to one of claims 1 to 3, wherein the low molecular weight heparin is dalteparin.

15 14. The method according to one of claims 1 to 3, wherein the low molecular weight heparin is tinzaparin.

15 15. The method according to one of claims 1 to 3, wherein the low molecular weight heparin is danaparoid.

20

16. The method according to one of claims 1 to 3, wherein the low molecular weight heparin is ardeparin.

25 17. The method according to one of claims 1 to 3, wherein the low molecular weight heparin is certoparin.

18. The method according to one of claims 1 to 3, wherein the low molecular weight heparin is CY222.<sup>110-200</sup>

30 19. The method according to one of claims 1 to 3, wherein the low molecular weight heparin is SR90107/ORG31540.